Vaccinex Provides Update on Pepinemab Study for Alzheimer’s Disease
ROCHESTER, N.Y. — Vaccinex, Inc. (NASDAQ: VCNX), a forward-thinking biotechnology firm, is making significant strides in the treatment of Alzheimer's disease (AD) and cancer. The company is focused on a unique approach through the inhibition of Semaphorin 4D (SEMA4D). Recently, it was announced that promising new efficacy and safety data from the randomized, double-blind, Phase 1b/2 SIGNAL-AD study, centered around pepinemab treatment for Alzheimer's disease, will be showcased at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) Conference. This milestone will be presented by Elizabeth Evans, PhD, the Chief Operating Officer, during a podium presentation.
Details of the Presentation
The presentation is titled "Results of SIGNAL-AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of pepinemab, anti-SEMA4D antibody believed to block reactive astrogliosis, in patients with Mild Cognitive Impairment (MCI) and Mild Dementia due to AD." This session will take place on a Thursday, at 2:55 PM Central European Time, which corresponds to 9:55 AM EDT, at the Madrid Marriott Auditorium Hotel and Conference Center.
Understanding the Study Outcomes
Key details surrounding the SIGNAL-AD study reveal several intriguing findings. Vaccinex researchers have identified that Semaphorin 4D (SEMA4D) significantly increases in stressed or damaged neurons during the development of Alzheimer's disease. This molecule interacts with plexin-B1 receptors present on astrocytes, the essential brain cells that help maintain neuron health. When SEMA4D binds to these receptors, astrocytes switch from offering crucial support to exhibiting inflammatory behavior, thus exacerbating the progression of Alzheimer's disease.
The Hypothesis Behind Pepinemab Treatment
In the SIGNAL-AD study, Vaccinex is testing a compelling hypothesis: administering the pepinemab antibody, which attaches to SEMA4D, can inhibit harmful signaling through astrocyte receptors and potentially mitigate the adverse effects of astrocyte activation. Previous studies have indicated that blocking SEMA4D can preserve healthy astrocyte functions and may slow down disease advancement in conditions like Huntington's disease.
Markers of Alzheimer's Disease Progression
The SIGNAL-AD trial will evaluate the effects of pepinemab on cognitive decline, along with examining biomarkers that indicate disease progression. The deposition of amyloid-beta (A?) in the brain is critical as it marks the beginning of the pathological changes leading to Alzheimer’s disease. These aggregates are believed to initiate a cascade of events, including increased astrocyte reactivity and the formation of toxic tau tangles within neurons, which are major contributors to neurodegeneration.
Preclinical Models and Vascular Effects
Moreover, the research will highlight how pepinemab influences levels of notable soluble biomarkers related to astrocytes and neuronal health, which are essential for understanding the treatment effects. Some existing therapies have been associated with damaging the brain’s vascular integrity, causing inflammation and microhemorrhages. Vaccinex is set to share fresh preclinical evidence indicating the beneficial effects of pepinemab on brain vasculature.
Funding and Support for the SIGNAL-AD Study
The SIGNAL-AD study has received funding from reputable sources, including a grant from the Alzheimer's Association and contributions from the Alzheimer's Drug Discovery Foundation (ADDF), which underscores the community's confidence in this innovative approach.
About Pepinemab
Pepinemab, the lead candidate developed by Vaccinex, is a humanized IgG4 monoclonal antibody specifically designed to inhibit SEMA4D. This compound has demonstrated favorable tolerability and safety in several clinical trials across neurological and oncology indications. The goal is to leverage this treatment in various circumstances where chronic inflammation is damaging either neural functions or tumor defenses.
About Vaccinex Inc.
Vaccinex, Inc. is dedicated to developing innovative therapies aimed at combating neurodegenerative diseases and cancer by targeting semaphorin 4D (SEMA4D). Pepinemab positions itself as a cornerstone in their clinical research efforts across several ailments, including its ongoing involvement in Alzheimer's disease through the SIGNAL-AD trial, and previously reported encouraging data in Huntington’s disease. Pepinemab's potential expands beyond neuroscience, with ongoing studies exploring its role in oncology, particularly in combination with established therapies for treating head and neck cancers and pancreatic adenocarcinoma.
Frequently Asked Questions
What is the main focus of the SIGNAL-AD study?
The SIGNAL-AD study primarily evaluates the safety and efficacy of pepinemab in patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer's disease.
Who will present the findings at the CTAD conference?
Elizabeth Evans, PhD, Chief Operating Officer of Vaccinex, will be presenting the findings.
What is the significance of SEMA4D in Alzheimer's disease?
SEMA4D is a molecule that binds to receptors on astrocytes, leading to neurotoxic activity that can exacerbate Alzheimer's disease.
Why is pepinemab important in this context?
Pepinemab aims to block SEMA4D, potentially preventing the neurotoxic inflammatory responses that worsen Alzheimer's disease symptoms.
What supportive evidence exists for pepinemab's effects?
Preliminary studies suggest that pepinemab may protect healthy astrocyte functions and slow progression in related diseases like Huntington's disease.
